专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US09688738B2 Immunotherapy against ErbB-3 receptor 有权
公开(公告)号：US09688738B2
公开(公告)日：2017-06-27
申请号：US13882899
申请日：2011-11-02
申请人： Luigi Aurisicchio , Gennaro Ciliberto , Rita Mancini , Emanuele Marra , Guiseppe Roscilli
发明人： Luigi Aurisicchio , Gennaro Ciliberto , Rita Mancini , Emanuele Marra , Guiseppe Roscilli
IPC分类号： A61K39/395 , C07K16/30 , C07K14/705 , A61K38/17 , A61K39/00 , C07K14/71 , C07K16/32 , A61K45/06 , A61K31/7088
CPC分类号： C07K14/705 , A61K31/7088 , A61K38/179 , A61K39/0011 , A61K45/06 , A61K2039/507 , A61K2039/53 , C07K14/71 , C07K16/32 , C07K2317/24 , C07K2317/34 , C07K2317/565 , C07K2317/73 , C07K2317/76 , A61K2300/00
摘要： The present invention describes methods and pharmaceutical compositions for the treatment of cancer in mammals, more particularly in human subjects. More specifically, the invention concerns anti-tumor vaccines based upon plasmid DNA and/or genetic vectors carrying a codon-usage optimized sequence and coding for a mutant form of the ErbB-3 receptor. Furthermore, the invention refers to monoclonal antibodies directed against the ErbB-3 receptor, obtained using these methods and capable to block its activity in cancer cells.

2. 发明授权

US06960558B2 Method of screening for anti-obesity agents using ciliary neutrophic factor receptor 有权
标题翻译：筛选使用睫状中性白细胞因子受体的抗肥胖剂的方法
公开(公告)号：US06960558B2
公开(公告)日：2005-11-01
申请号：US10356191
申请日：2003-01-31
申请人： Gennaro Ciliberto , Isabelle Gloaguen , Annalise Di Marco , Anna Demartis , Ralph Laufer , Riccardo Cortese
发明人： Gennaro Ciliberto , Isabelle Gloaguen , Annalise Di Marco , Anna Demartis , Ralph Laufer , Riccardo Cortese
IPC分类号： A61K45/00 , A61K38/00 , A61K38/18 , A61K38/22 , A61K48/00 , A61P3/04 , A61P3/10 , A61P43/00 , A61K31/00 , G01N33/53
CPC分类号： A61K38/185 , A61K38/2264 , A61K48/00 , A61K2300/00
摘要： The present invention relates to methods for screening for anti-obesity agents using the ciliary neutrophic factor receptor.
摘要翻译：本发明涉及使用睫状中性因子受体筛选抗肥胖剂的方法。

3. 发明授权

US06641807B1 Adenoviral vectors encoding erythropoietin and their use in gene therapy 失效
标题翻译：编码促红细胞生成素的腺病毒载体及其在基因治疗中的应用
公开(公告)号：US06641807B1
公开(公告)日：2003-11-04
申请号：US09762668
申请日：2001-04-23
申请人： Rocco Savino , Gennaro Ciliberto , Nicola La Monica
发明人： Rocco Savino , Gennaro Ciliberto , Nicola La Monica
IPC分类号： A01N6300
CPC分类号： A61K38/1816 , A61K48/00 , C07K14/505 , C12N2799/022
摘要： Helper dependent adenoviral vectors encoding erythropoietin (epo) provide high levels of epo to achieve a long-term therapeutically effective dosage, and allow for repeat administration to patients with disorders such as anaemia of Chronic Renal Failure (CFR), anaemias due to beta-thalassaemia, and sickle cell anaemia (SCA).
摘要翻译：编码促红细胞生成素（epo）的辅助依赖性腺病毒载体提供高水平的epo以实现长期治疗有效剂量，并且允许对患有慢性肾功能衰竭（CFR）的贫血，由于β-地中海贫血造成的贫血的疾病患者重复施用，和镰状细胞性贫血（SCA）。

4. 发明申请

US20140017259A1 IMMUNOTHERAPY AGAINST ERBB-3 RECEPTOR 有权
标题翻译：对ERBB-3受体的免疫治疗
公开(公告)号：US20140017259A1
公开(公告)日：2014-01-16
申请号：US13882899
申请日：2011-11-02
申请人： Luigi Aurisicchio , Gennaro Ciliberto , Rita Mancini , Emanuele Marra , Guiseppe Roscilli
发明人： Luigi Aurisicchio , Gennaro Ciliberto , Rita Mancini , Emanuele Marra , Guiseppe Roscilli
IPC分类号： C07K14/705
CPC分类号： C07K14/705 , A61K31/7088 , A61K38/179 , A61K39/0011 , A61K45/06 , A61K2039/507 , A61K2039/53 , C07K14/71 , C07K16/32 , C07K2317/24 , C07K2317/34 , C07K2317/565 , C07K2317/73 , C07K2317/76 , A61K2300/00
摘要： The present invention describes methods and pharmaceutical compositions for the treatment of cancer in mammals, more particularly in human subjects. More specifically, the invention concerns anti-tumor vaccines based upon plasmid DNA and/or genetic vectors carrying a codon-usage optimized sequence and coding for a mutant form of the ErbB-3 receptor. Furthermore, the invention refers to monoclonal antibodies directed against the ErbB-3 receptor, obtained using these methods and capable to block its activity in cancer cells.
摘要翻译：本发明描述了用于治疗哺乳动物癌症的方法和药物组合物，更特别在人类受试者中。更具体地，本发明涉及基于携带密码子使用优化序列并编码ErbB-3受体的突变体形式的质粒DNA和/或遗传载体的抗肿瘤疫苗。此外，本发明涉及使用这些方法获得的能够阻断其在癌细胞中的活性的针对ErbB-3受体的单克隆抗体。

5. 发明授权

US08188244B2 Carcinoembryonic antigen fusions and uses thereof 有权
标题翻译：癌胚抗原融合物及其用途
公开(公告)号：US08188244B2
公开(公告)日：2012-05-29
申请号：US10589180
申请日：2005-02-03
申请人： Nicola La Monica , Andrea Facciabene , Luigi Aurisicchio , Gennaro Ciliberto
发明人： Nicola La Monica , Andrea Facciabene , Luigi Aurisicchio , Gennaro Ciliberto
IPC分类号： C12N15/11 , C12N15/63
CPC分类号： C07K14/70503 , A61K2039/53 , C07K2319/30 , C07K2319/55 , Y02A50/472
摘要： Polynucleotides encoding carcinoembryonic antigen (CEA) fusion proteins are provided, the CEA fusion proteins comprising a CEA protein, or functional variant thereof, fused to a substantial portion of an immunoenhancing element. The polynucleotides of the present invention can elicit an immune response in a mammal, which, in preferred embodiments, is stronger than the immune response elicited by a wild-type CEA. The gene encoding CEA is commonly associated with the development of human carcinomas. The present invention provides compositions and methods to elicit or enhance immunity to the protein product expressed by the CEA tumor-associated antigen, wherein aberrant CEA expression is associated with a carcinoma or its development. This invention specifically provides adenoviral vector and plasmid constructs carrying polynucleotides encoding CEA fusion proteins and discloses their use in vaccines and pharmaceutical compositions for preventing and treating cancer.
摘要翻译：提供了编码癌胚抗原（CEA）融合蛋白的多核苷酸，包含CEA蛋白或其功能变体的CEA融合蛋白与免疫增强元件的大部分融合。本发明的多核苷酸可以在哺乳动物中引发免疫应答，在优选的实施方案中，它们比由野生型CEA引起的免疫应答更强。编码CEA的基因通常与人类癌的发展有关。本发明提供了引发或增强由CEA肿瘤相关抗原表达的蛋白质产物的免疫的组合物和方法，其中异常CEA表达与癌症或其发展相关。本发明具体提供携带编码CEA融合蛋白的多核苷酸的腺病毒载体和质粒构建体，并公开了其用于预防和治疗癌症的疫苗和药物组合物中。

6. 发明授权

US08106176B2 Matrix metalloproteinase 11 vaccine 有权
标题翻译：基质金属蛋白酶11疫苗
公开(公告)号：US08106176B2
公开(公告)日：2012-01-31
申请号：US12083031
申请日：2006-10-03
申请人： Luigi Aurisicchio , Daniela Peruzzi , Nicola La Monica , Gennaro Ciliberto , Domenico Lazzaro , Federica Mori
发明人： Luigi Aurisicchio , Daniela Peruzzi , Nicola La Monica , Gennaro Ciliberto , Domenico Lazzaro , Federica Mori
IPC分类号： C07H1/00 , C07H5/04 , C07H5/06 , C07H19/00 , C07H21/00 , C07H21/04 , C08B37/00 , C12P21/06 , C12N5/00 , C12N5/02
CPC分类号： C12N9/6416 , A61K39/00 , C07K2319/00 , Y02A50/472
摘要： Compositions comprising matrix metalloproteinase 11 (MMP-11) or stromelysin-3 (ST-3) or the nucleic acid encoding the MMP-11 for use in vaccines for treating tumors and cancers, which overexpress MMP-11, are described. In particular embodiments, the compositions comprise a nucleic acid encoding a fusion polypeptide that includes the catalytically inactivated MMP-11 linked at the C-terminus to an immunoenhancing element wherein the codons encoding the MMP-11 and the immunoenhancing element have been optimized for enhanced expression of the fusion polypeptide in human cells. In other embodiments, the compositions comprise the catalytically inactivated MMP-11 linked at the C-terminus to an immunoenhancing element. The compositions can be used alone or in synergy with vaccines against other tumor associated antigens as well as with conventional therapies such as radiation therapy and chemotherapy.
摘要翻译：描述了包含基质金属蛋白酶11（MMP-11）或基质溶素-3（ST-3）的组合物或编码用于治疗过表达MMP-11的肿瘤和癌症的疫苗中的MMP-11的核酸。在具体实施方案中，组合物包含编码融合多肽的核酸，其包含在C-末端连接至免疫增强元件的催化失活的MMP-11，其中编码MMP-11和免疫增强元件的密码子已被优化以增强表达的人类细胞中的融合多肽。在其它实施方案中，组合物包含在C末端与免疫增强元件连接的催化失活的MMP-11。组合物可以单独使用或与抗其他肿瘤相关抗原的疫苗以及常规疗法如放射治疗和化学疗法协同使用。

7. 发明授权

US06706261B1 Compositions and methods comprising immunogenic muteins of interleukin-6 失效
标题翻译：包含白介素-6的免疫原性突变蛋白的组合物和方法
公开(公告)号：US06706261B1
公开(公告)日：2004-03-16
申请号：US09559950
申请日：2000-04-27
申请人： Gennaro Ciliberto , Rocco Savino , Riccardo Cortese
发明人： Gennaro Ciliberto , Rocco Savino , Riccardo Cortese
IPC分类号： C07K1454
CPC分类号： A61K39/0008 , A61K2039/55505
摘要： Cytokines, including muteins thereof, which are biologically inactive in humans but remain immunogenic, are used in pharmaceutical compositions to promote a neutralizing immune response against native cytokines when administered to a subject in need thereof to treat homeostatic disorders and disorders associated with an overproduction of cytokines.
摘要翻译：在药物组合物中使用细胞因子，包括其在人体中具有生物学活性但保持免疫原性的突变蛋白，以在施用于有需要的受试者时治疗对于天然细胞因子的中和免疫应答，以治疗与细胞因子过量产生相关的体内平衡疾病和病症。

8. 发明授权

US5891998A Interleukin-6 receptor agonists 失效
标题翻译：白细胞介素-6受体激动剂
公开(公告)号：US5891998A
公开(公告)日：1999-04-06
申请号：US567048
申请日：1995-12-04
申请人： Rocco Savino , Armin Lahm , Gennaro Ciliberto
发明人： Rocco Savino , Armin Lahm , Gennaro Ciliberto
IPC分类号： C07K14/475 , C07K14/52 , C07K14/54 , C12N15/24 , G01N33/68 , G01N33/74 , C12N5/10 , C12N15/63
CPC分类号： C07K14/52 , C07K14/475 , C07K14/5412 , G01N33/6863 , G01N33/6869 , G01N33/6872 , G01N33/74 , C07K2319/00 , G01N2500/00 , Y10S930/14
摘要： Disclosed are interleukin-6 receptor agonists. These receptor agonists wereenerated by mutating amino acid positions 175, 176, 177, 181, and/or 183 of human interleukin-6.
摘要翻译：公开了白细胞介素-6受体激动剂。这些受体激动剂是通过突变人白细胞介素-6的氨基酸位置175,176,177,181和/或183产生的。

9. 发明授权

US08492522B2 Matrix metalloproteinase 11 vaccine 有权
标题翻译：基质金属蛋白酶11疫苗
公开(公告)号：US08492522B2
公开(公告)日：2013-07-23
申请号：US13332580
申请日：2011-12-21
申请人： Luigi Aurisicchio , Daniela Peruzzi , Nicola La Monica , Gennaro Ciliberto , Domenico Lazzaro , Federica Mori
发明人： Luigi Aurisicchio , Daniela Peruzzi , Nicola La Monica , Gennaro Ciliberto , Domenico Lazzaro , Federica Mori
IPC分类号： C07K1/00 , C07K14/00 , C07K17/00 , G01N33/00
CPC分类号： C12N9/6416 , A61K39/00 , C07K2319/00 , Y02A50/472
摘要： Compositions comprising matrix metalloproteinase 11 (MMP-11) or stromelysin-3 (ST-3) or the nucleic acid encoding the MMP-11 for use in vaccines for treating tumors and cancers, which overexpress MMP-11, are described. In particular embodiments, the compositions comprise a nucleic acid encoding a fusion polypeptide that includes the catalytically inactivated MMP-11 linked at the C-terminus to an immunoenhancing element wherein the codons encoding the MMP-11 and the immunoenhancing element have been optimized for enhanced expression of the fusion polypeptide in human cells. In other embodiments, the compositions comprise the catalytically inactivated MMP-11 linked at the C-terminus to an immunoenhancing element. The compositions can be used alone or in synergy with vaccines against other tumor associated antigens as well as with conventional therapies such as radiation therapy and chemotherapy.
摘要翻译：描述了包含基质金属蛋白酶11（MMP-11）或基质溶素-3（ST-3）的组合物或编码用于治疗过表达MMP-11的肿瘤和癌症的疫苗中的MMP-11的核酸。在具体实施方案中，组合物包含编码融合多肽的核酸，其包含在C-末端连接至免疫增强元件的催化失活的MMP-11，其中编码MMP-11和免疫增强元件的密码子已被优化以增强表达的人类细胞中的融合多肽。在其它实施方案中，组合物包含在C末端与免疫增强元件连接的催化失活的MMP-11。组合物可以单独使用或与抗其他肿瘤相关抗原的疫苗以及常规疗法如放射治疗和化学疗法协同使用。

10. 发明申请

US20120177679A1 MATRIX METALLOPROTEINASE 11 VACCINE 有权
公开(公告)号：US20120177679A1
公开(公告)日：2012-07-12
申请号：US13332580
申请日：2011-12-21
申请人： LUIGI AURISICCHIO , DANIELA PERUZZI , NICOLA LA MONICA , GENNARO CILIBERTO , DOMENICO LAZZARO , FEDERICA MORI
发明人： LUIGI AURISICCHIO , DANIELA PERUZZI , NICOLA LA MONICA , GENNARO CILIBERTO , DOMENICO LAZZARO , FEDERICA MORI
IPC分类号： A61K39/385 , C12N9/96 , A61P35/00
CPC分类号： C12N9/6416 , A61K39/00 , C07K2319/00 , Y02A50/472
摘要： Compositions comprising matrix metalloproteinase 11 (MMP-11) or stromelysin-3 (ST-3) or the nucleic acid encoding the MMP-11 for use in vaccines for treating tumors and cancers, which overexpress MMP-11, are described. In particular embodiments, the compositions comprise a nucleic acid encoding a fusion polypeptide that includes the catalytically inactivated MMP-11 linked at the C-terminus to an immunoenhancing element wherein the codons encoding the MMP-11 and the immunoenhancing element have been optimized for enhanced expression of the fusion polypeptide in human cells. In other embodiments, the compositions comprise the catalytically inactivated MMP-11 linked at the C-terminus to an immunoenhancing element. The compositions can be used alone or in synergy with vaccines against other tumor associated antigens as well as with conventional therapies such as radiation therapy and chemotherapy.
摘要翻译：描述了包含基质金属蛋白酶11（MMP-11）或基质溶素-3（ST-3）的组合物或编码用于治疗过表达MMP-11的肿瘤和癌症的疫苗中的MMP-11的核酸。在具体实施方案中，组合物包含编码融合多肽的核酸，其包含在C-末端连接至免疫增强元件的催化失活的MMP-11，其中编码MMP-11和免疫增强元件的密码子已被优化以增强表达的人类细胞中的融合多肽。在其它实施方案中，组合物包含在C末端与免疫增强元件连接的催化失活的MMP-11。组合物可以单独使用或与抗其他肿瘤相关抗原的疫苗以及常规疗法如放射治疗和化学疗法协同使用。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式